LBA14_PR - IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

Enrique Grande ,U.F.F De Giorgi,S.H Park,J.-R Li,Ann Christine Thåström ,Ian D Davis ,Maria De Santis ,Matt D Galsky ,Arash Rezazadeh Kalebasty ,Fabio A.b Schutz ,Xavier García Del Muro ,Sanjeev Mariathasan ,Eiji Kikuchi ,B Ya Alekseev ,Mahmut Gümüş ,Almut Mecke ,Marina Mencinger ,Mustafa Özgüroğlu ,J.á Arranz Arija ,Aristotelis Bamias

doi:10.1093/annonc/mdz394.047

Abstract

LBA14_PR - IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

Full Text